| Medical and Health Sciences | 2021-2025 | 446 | DE 24 | 99.90 |
| Hematology | Lifetime | 47 | DE 5 | 99.73 |
| Medical Genetics | Lifetime | 118 | DE 14 | 99.14 |
| Oncology | Lifetime | 713 | DE 22 | 98.55 |
| Hematology | 2021-2025 | 20 | DE 4 | 99.65 |
| Medical Genetics | 2021-2025 | 51 | DE 9 | 98.73 |
| Oncology | 2021-2025 | 375 | DE 23 | 95.87 |
| Public, Environmental and Occupational Health | 2021-2025 | 946 | DE 25 | 90.26 |
| Immunology | 2021-2025 | 676 | DE 47 | 79.26 |
| Hematopoietic Stem Cell Transplantation | Lifetime | 32 | DE 1 | 99.80 |
| Acute Myeloid Leukemia Research | Lifetime | 66 | DE 10 | 99.74 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 28 | DE 4 | 99.65 |
| Multiple Myeloma Research and Treatments | Lifetime | 58 | DE 4 | 99.55 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 61 | DE 6 | 99.63 |
| Acute Lymphoblastic Leukemia research | Lifetime | 93 | DE 4 | 99.55 |
| Eosinophilic Disorders and Syndromes | Lifetime | 111 | DE 4 | 98.96 |
| Polyomavirus and related diseases | Lifetime | 112 | DE 7 | 98.56 |
| Kruppel-like factors research | Lifetime | 69 | DE 3 | 98.23 |
| Neutropenia and Cancer Infections | Lifetime | 165 | DE 17 | 98.26 |
| Cancer Treatment and Pharmacology | Lifetime | 527 | DE 24 | 98.54 |
| CAR-T cell therapy research | Lifetime | 715 | DE 64 | 98.09 |
| Renal Transplantation Outcomes and Treatments | Lifetime | 748 | DE 50 | 97.37 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 550 | DE 13 | 95.99 |
| Protein Degradation and Inhibitors | Lifetime | 849 | DE 64 | 94.54 |
| Hematopoietic Stem Cell Transplantation | 2021-2025 | 3 | DE 1 | 99.84 |
| Acute Myeloid Leukemia Research | 2021-2025 | 30 | DE 5 | 99.68 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 23 | DE 3 | 99.33 |
| Acute Lymphoblastic Leukemia research | 2021-2025 | 67 | DE 2 | 98.62 |
| Chronic Myeloid Leukemia Treatments | 2021-2025 | 55 | DE 3 | 98.97 |
| CAR-T cell therapy research | 2021-2025 | 587 | DE 48 | 96.48 |
| Immune Cell Function and Interaction | 2021-2025 | 585 | DE 41 | 93.66 |
| Kruppel-like factors research | 2021-2025 | 30 | DE 3 | 94.40 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 480 | DE 33 | 95.21 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 125 | DE 5 | 94.59 |
| T-cell and B-cell Immunology | 2021-2025 | 368 | DE 27 | 91.40 |
| Polyomavirus and related diseases | 2021-2025 | 142 | DE 15 | 91.92 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 640 | DE 43 | 91.66 |
| Renal Transplantation Outcomes and Treatments | 2021-2025 | 652 | DE 27 | 90.13 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 374 | DE 7 | 87.38 |
| Neutropenia and Cancer Infections | 2021-2025 | 354 | DE 21 | 81.32 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 617 | DE 54 | 80.40 |
